Vascular Neurology Committee, Beijing Neuroscience Society, Experts Group of Chinese Consensus on Argatroban for Treatment of Acute Ischemic Stroke. Chinese Consensus on Argatroban for Treatment of Acute Ischemic Stroke 2021[J]. Chinese Journal of Stroke, 2021, 16(09): 946-953.
[1] 《中国脑卒中防治报告》编写组. 《中国脑卒中防
治报告2019》概要[J]. 中国脑血管病杂志，2020，17
（5）：272-281.
[2] 王陇德，毛群安，张宗久. 中国脑卒中防治报告[M].
北京：人民卫生出版社，2018：3-11.
[3] 中华医学会神经病学分会，中华医学会神经病学分
会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺
血发作二级预防指南2014[J]. 中华神经科杂志，2015，
48（4）：258-273.
[4] 中华医学会神经病学分会，中华医学会神经病学分
会脑血管病学组. 中国急性缺血性脑卒中诊治指南
2018[J]. 中华神经科杂志，2018，51（9）：666-682.
[5] 中华医学会神经病学分会，中华医学会神经病学分
会神经康复学组，中华医学会神经病学分会脑血管
病学组. 中国脑卒中早期康复治疗指南[J]. 中华神经
科杂志，2017，50（6）：405-412.
[6] International Stroke Trial Collaborative Group. The
international stroke trial（IST）：a randomised trial
of aspirin，subcutaneous heparin，both，or neither
among 19 435 patients with acute ischaemic stroke[J].
Lancet，1997，349（9065）：1569-1581.
[7] BATH P M，LINDENSTROM E，BOYSEN G，et
al. Tinzaparin in acute ischaemic stroke（TAIST）：a
randomised aspirin-controlled trial[J]. Lancet，2001，
358（9283）：702-710.
[8] SANDERCOCK P A，COUNSELL C，KANE
E J. Anticoagulants for acute ischaemic
stroke[J/OL]. Cochrane Database Syst Rev，
2015，3：CD000024[2021-07-11]. https：//doi.
org/10.1002/14651858.cd000024.pub4.
[9] FROIO N L，MURDOCH M R，ELIAS D N，et
al. Anticoagulation in acute ischemic stroke：a
systematic search[J]. Revista Da Associacao Medica
Brasileira，2017，63（1）：50-56.
[10] HIDENOBU I. Development of argatroban as an
anticoagulant and antithrombin agent in Japan[J/
OL]. Pathophysiol Haemost Thromb，2002，32
（Suppl 3）：23-28[2021-07-11]. https：//doi.
org/10.1159/000069105.
[11] LAMONTE M P，NASH M L，WANG D Z，et
al. Argatroban anticoagulation in patients with
acute ischemic stroke（ARGIS-1）：a randomized，
placebo-controlled safety study[J]. Stroke，2004，35
（7）：1677-1682.
[12] WADA T，YASUNAGA H，HORIGUCHI H，et al.
Outcomes of argatroban treatment in patients with
atherothrombotic stroke：observational nationwide
study in Japan[J]. Stroke，2016，47（2）：471-476.
[13] GARCIA D A，BAGLIN T P，WEITZ J I，et al.
Parenteral anticoagulants：antithrombotic therapy
and prevention of thrombosis，9th ed：American
College of Chest Physicians evidence-based clinical
practice guidelines[J/OL]. Chest，2012，141（2
Suppl）：e24S-e43S[2021-07-11]. https：//doi.
org/10.1378/chest.11-2291.
[14] LINKINS L A，DANS A L，MOORES L K，et
al. Treatment and prevention of heparin-induced
thrombocytopenia：antithrombotic therapy and
prevention of thrombosis，9th ed：American
College of Chest Physicians evidence-based clinical
practice guidelines[J/OL]. Chest，2012，141（2
Suppl）：e495S-e530S[2021-07-11]. https：//10.1378/
chest.11-2303.
[15] ALITER K F，AL-HORANI R A. Thrombin
inhibition by argatroban：potential therapeutic
benefits in COVID-19[J]. Cardiovasc Drugs Ther，
2021，35（2）：195-203.
[16] POWERS W J，RABINSTEIN A A，ACKERSON
T，et al. Guidelines for the early management of
patients with acute ischemic stroke：2019 update
to the 2018 guidelines for the early management of
acute ischemic stroke：a guideline for healthcare
professionals from the American Heart Association/
American Stroke Association[J/OL]. Stroke，2019，
50（12）：e344-e418[2021-07-11]. https：//doi.
org/10.1161/str.0000000000000211.
[17] LIP G Y H，BANERJEE A，BORIANI G，et al.
Antithrombotic therapy for atrial fibrillation：CHEST
guideline and expert panel report[J]. Chest，2018，
154（5）：1121-1201.
[18] KOBAYASHI S，TAZAKI Y. Effect of the thrombin
inhibitor argatroban in acute cerebral thrombosis[J].
Semin Thromb Hemost，1997，23（6）：531-534.
[19] JESKE W P，FAREED J，HOPPENSTEADT D A，
et al. Pharmacology of argatroban[J]. Expert Rev
Hematol，2010，3（5）：527-539.
[20] BAUER M，BRANDSTETTER H，TURK D，et
al. Crystallographic determination of thrombin
complexes with small synthetic inhibitors as a
starting point for the receptor-based design of
antithrombotics[J]. Semin Thromb Hemost，1993，19
（4）：352-360.
[21] YEH R W，JANG I K. Argatroban：update[J]. Am
Heart J，2006，151（6）：1131-1138.
[22] WALENGA J M，FASANELLA A R，IQBAL O，et
al. Coagulation laboratory testing in patients treated
with argatroban[J]. Semin Thromb Hemost，1999，25
（Suppl 1）：61-66.
[23] HURSTING M J，ALFORD K L，BECKER J C，
et al. Novastan（brand of argatroban）：a smallmolecule，
direct thrombin inhibitor[J]. Semin
Thromb Hemost，1997，23（6）：503-516.
[24] CHEN S M，CAI D C，HUANG P C，et al. Early
and long-term outcomes of argatroban use in patients
with acute noncardioembolic stroke[J/OL]. Clin
Neurol Neurosurg，2020，198：106233[2021-07-11].
https：//doi.org/10.1016/j.clineuro.2020.106233.
[25] PARK J S，PARK S S，KOH E J，et al. Treatment
for patients with acute ischemic stroke presenting
beyond six hours of ischemic symptom onset：
effectiveness of intravenous direct thrombin inhibitor，
argatroban[J]. J Korean Neurosurg Soc，2010，47（4）：
258-264.
[26] HOSOMI N，NAYA T，KOHNO M，et al. Efficacy
of anti-coagulant treatment with argatroban on
cardioembolic stroke[J]. J Neurol，2007，254（5）：
605-612.
[27] URABE T，TANAKA R，NODA K，et al.
Anticoagulant therapy with a selective thrombin
inhibitor for acute cerebral infarction：usefulness of
coagulation markers for evaluation of efficacy[J]. J
Thromb Thrombolysis，2002，13（3）：155-160.
[28] OGURO H，MITAKI S，TAKAYOSHI H，et al.
Retrospective analysis of argatroban in 353 patients
with acute noncardioembolic stroke[J]. J Stroke
Cerebrovasc Dis，2018，27（8）：2175-2181.
[29] LAMONTE M P，BROWN P M，HURSTING
M J. Stroke in patients with heparin-induced
thrombocytopenia and the effect of argatroban
therapy[J]. Crit Care Med，2004，32（4）：976-980.
[30] CHEN L，CAO S S，YANG J X. Argatroban plus
aspirin versus aspirin in acute ischemic stroke[J].
Neurol Res，2018，40（10）：862-867.
[31] ZHOU L S，LI X Q，ZHOU Z H，et al. Effect
of argatroban combined with dual antiplatelet
therapy on early neurological deterioration
in acute minor posterior circulation ischemic
stroke[J/OL]. Clin Appl Thromb Hemost，2020，
26：1076029620904131[2021-07-11]. https：//doi.
org/10.1177/1076029620904131.
[32] NISHI R，MANO T，KOBAYASHI Y，et al.
Argatroban，aspirin，and clopidogrel combination
therapy for acute penetrating artery infarction：a
pilot study[J]. Brain Nerve，2016，68（2）：181-189.
[33] NAGAKANE Y，TANAKA E，ASHIDA S，et al.
Safety of dual antiplatelet therapy with argatroban in
patients with acute ischemic stroke[J]. Brain Nerve，
2018，70（5）：557-562.
[34] BARRETO A D，ALEXANDROV A V，LYDEN P，
et al. The argatroban and tissue-type plasminogen
activator stroke study：final results of a pilot safety
study[J]. Stroke，2012，43（3）：770-775.
[35] BARRETO A D，FORD G A，SHEN L，et
al. Randomized，multicenter trial of ARTSS-2
（argatroban with recombinant tissue plasminogen
activator for acute stroke）[J]. Stroke，2017，48（6）：
1608-1616.
[36] BEREKASHVILI K，SOOMRO J，SHEN L，et al.
Safety and feasibility of argatroban，recombinant
tissue plasminogen activator，and intra-arterial
therapy in stroke（ARTSS-IA Study）[J]. J Stroke
Cerebrovasc Dis，2018，27（12）：3647-3651.
[37] KIM J，YI H J，LEE D H，et al. Safety and feasibility
of using argatroban immediately after mechanical
thrombectomy for large artery occlusion[J/OL].
World Neurosurg，2019，132：e341-e349[2021-07-11].
https：//doi.org/ 10.1016/j.wneu.2019.08.151.
